In primary transplantation assays, the survival rate between wild type and Necdin null groups was comparable (Figure 2C); However, Necdin deficiency significantly delayed the development of leukemia induced by MLL-AF9 in secondary transplantation assays (Figure 2D). The gene discussed is MLLT3; the disease is leukemia.